Human Papillomavirus Testing in Cervical Cancer Screening

Obstetrics and Gynecology Clinics of North America

Volumn 40, Issue 2, 2013, Pages 377-390

  Castle, Philip E ^a   Cremer, Miriam ^b,c  

^a Global Cancer Initiative   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus (HPV); Low resource settings; Pap testing; Screening; Vaccination; Visual inspection after acetic acid (VIA)

Indexed keywords

ACETIC ACID; PROTEIN E6; VIRUS DNA; WART VIRUS VACCINE;

CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DEVICE APPROVAL; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; EARLY CANCER; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DISPARITY; HEALTH PROGRAM; HUMAN; LASER COAGULATION; MEDICAL SOCIETY; MEDICALLY UNDERSERVED; MOLECULAR DIAGNOSIS; MORBIDITY; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRECANCER; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SOCIAL STATUS; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MASS SCREENING; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84878625615     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2013.03.002     Document Type: Review

References (56)

1. Cervix cancer screening. IARC Handbooks of cancer prevention 2005, vol. 10. IARC Press, Lyons (France).
2. Wright T.C., Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003, 348(6):489-490.
3. Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907.
4. Rodriguez A.C., Schiffman M., Herrero R., et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010, 102(5):315-324.
5. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119(5):1095-1101.
6. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357(16):1579-1588.
7. Naucler P., Ryd W., Tornberg S., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357(16):1589-1597.
8. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11(3):249-257.
9. Anttila A., Kotaniemi-Talonen L., Leinonen M., et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:c1804. 10.1136/bmj.c1804.
10. Rijkaart D.C., Berkhof J., Rozendaal L., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13(1):78-88.
11. Castle P.E., Fetterman B., Poitras N., et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011, 117(3):650-656.
12. Arbyn M., Ronco G., Anttila A., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl 5):F88-F99. 10.1016/j.vaccine.2012.06.095.
13. Sankaranarayanan R., Nene B.M., Shastri S.S., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360(14):1385-1394.
14. Castle P.E., Glass A.G., Rush B.B., et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012, 30(25):3044-3050.
15. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003, 95(1):46-52.
16. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
17. McCredie M.R., Sharples K.J., Paul C., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008, 9(5):425-434.
18. Castle P.E., Fetterman B., Poitras N., et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009, 113(3):595-600.
19. Katki H.A., Kinney W.K., Fetterman B., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12(7):663-672.
20. Castle P.E., Rodriguez A.C., Burk R.D., et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009, 339:b2569.
21. Kjaer S.K., Frederiksen K., Munk C., et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102(19):1478-1488.
22. Cuschieri K., Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008, 17(10):2536-2545.
23. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008, 100(5):308-320.
24. de Kok I.M., van R.J., Dillner J., et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012, 344:e670.
25. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001, 93(4):293-299.
26. Wright T.C., Cox J.T., Massad L.S., et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287(16):2120-2129.
27. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52(6):342-362.
28. ACOG Committee on Practice Bulletins-Gynecology ACOG Practice Bulletin No. 109: cervical cytology screening. Obstet Gynecol 2009, 114(6):1409-1420.
29. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012 Mar, 14:10.
30. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012, 62(3):147-172.
31. Committee on Practice Bulletins-Gynecology ACOG practice bulletin 131: screening for cervical cancer. Obstet Gynecol 2012, 120(5):1222-1238.
32. Saraiya M., Berkowitz Z., Yabroff K.R., et al. Cervical cancer screening with HPV and the Pap test vs. the Pap test alone: what screening intervals are physicians recommending?. Arch Intern Med 2010, 170(11):977-985.
33. Lee J.W., Berkowitz Z., Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 2011, 118(1):4-13.
34. Castle P.E., Fetterman B., Thomas C.J., et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010, 116(1):76-84.
35. Yabroff K.R., Saraiya M., Meissner H.I., et al. Specialty differences in primary care physician reports of Papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med 2009, 151(9):602-611.
36. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367(9509):489-498.
37. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
38. Freeman H.P., Wingrove B.K. Excess cervical cancer mortality: a marker for low access to health care in poor communities 2007, National Institutes of Health, Bethesda (MD), Report No.: 05-5282.
39. Simard E.P., Fedewa S., Ma J., et al. Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-2007. Cancer 2012, 118(20):5110-5116.
40. Scarinci I.C., Garcia F.A., Kobetz E., et al. Cervical cancer prevention: new tools and old barriers. Cancer 2010, 116(11):2531-2542.
41. Zhao F.H., Lewkowitz A.K., Chen F., et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst 2012, 104(3):178-188.
42. Balasubramanian A., Kulasingam S.L., Baer A., et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis 2010, 14(3):185-195.
43. Virtanen A., Nieminen P., Luostarinen T., et al. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011, 20(9):1960-1969.
44. Gok M., Heideman D.A., van Kemenade F.J., et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010, 340:c1040.
45. Gok M., Heideman D.A., van Kemenade F.J., et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders. Eur J Cancer 2012, 48(12):1799-1808.
46. Szarewski A., Cadman L., Mesher D., et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening-a randomised controlled trial. Br J Cancer 2011, 104(6):915-920.
47. Lindell M., Sanner K., Wikstrom I., et al. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG 2012, 119(2):245-248.
48. Castle P.E., Rausa A., Walls T., et al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med 2011, 52(6):452-455.
49. Ferlay J., Shin H.R., Bray F., et al. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer, Lyon (France).
50. Kitchener H.C., Castle P.E., Cox J.T. Achievements and limitations of cervical cytology screening. Vaccine 2006, 24(Suppl 3):S63-S70.
51. Qiao Y.L., Sellors J.W., Eder P.S., et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9(10):929-936.
52. Schweizer J., Lu P.S., Mahoney C.W., et al. Feasibility study of a human papillomavirus e6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010, 48(12):4646-4648.
53. Belinson J.L., Du H., Yang B., et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012, 130(8):1855-1860.
54. Gage J.C., Castle P.E. Preventing cervical cancer globally by acting locally: if not now, when?. J Natl Cancer Inst 2010, 102(20):1524-1527.
55. Stoler M.H., Castle P.E., Solomon D., et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007, 127(3):1-3.
56. Meijer C.J., Berkhof J., Castle P.E., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124(3):516-520.